PMID- 25738969
OWN - NLM
STAT- MEDLINE
DCOM- 20160108
LR  - 20181202
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 12
IP  - 1
DP  - 2015 Jul
TI  - Afzelin attenuates asthma phenotypes by downregulation of GATA3 in a murine model 
      of asthma.
PG  - 71-6
LID - 10.3892/mmr.2015.3391 [doi]
AB  - Asthma is a serious health problem causing significant mortality and morbidity 
      globally. Persistent airway inflammation, airway hyperresponsiveness, increased 
      immunoglobulin E (IgE) levels and mucus hypersecretion are key characteristics of 
      the condition. Asthma is mediated via a dominant T-helper 2 (Th2) immune 
      response, causing enhanced expression of Th2 cytokines. These cytokines are 
      responsible for the various pathological changes associated with allergic asthma. 
      To investigate the anti-asthmatic potential of afzelin, as well as the underlying 
      mechanisms involved, its anti-asthmatic potential were investigated in a murine 
      model of asthma. In the present study, BALB/c mice were systemically sensitized 
      using ovalbumin (OVA) followed by aerosol allergen challenges. The effect of 
      afzelin on airway hyperresponsiveness, eosinophilic infiltration, Th2 cytokine 
      and OVA‑specific IgE production in a mouse model of asthma were investigated. It 
      was found that afzelin‑treated groups suppressed eosinophil infiltration, 
      allergic airway inflammation, airway hyperresponsiveness, OVA-specific IgE and 
      Th2 cytokine secretion. The results of the present study suggested that the 
      therapeutic mechanism by which afzelin effectively treats asthma is based on 
      reduction of Th2 cytokine via inhibition of GATA-binding protein 3 transcription 
      factor, which is the master regulator of Th2 cytokine differentiation and 
      production.
FAU - Zhou, Wenbo
AU  - Zhou W
AD  - Department of Respiratory Diseases, Xuanwu Hospital, Capital Medical University, 
      Beijing 100053, P.R. China.
FAU - Nie, Xiuhong
AU  - Nie X
AD  - Department of Respiratory Diseases, Xuanwu Hospital, Capital Medical University, 
      Beijing 100053, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20150226
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Allergens)
RN  - 0 (Cytokines)
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (Gata3 protein, mouse)
RN  - 0 (Mannosides)
RN  - 0 (Proanthocyanidins)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 5M86W1YH7O (afzelin)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Allergens/toxicity
MH  - Animals
MH  - Asthma/chemically induced/*drug therapy/genetics/immunology
MH  - Bronchial Hyperreactivity/*genetics/immunology
MH  - Cytokines/genetics/metabolism
MH  - Disease Models, Animal
MH  - Eosinophils/*metabolism/pathology
MH  - GATA3 Transcription Factor/antagonists & inhibitors/*biosynthesis/genetics
MH  - Gene Expression Regulation
MH  - Humans
MH  - Immunoglobulin E/immunology/metabolism
MH  - Mannosides/*administration & dosage
MH  - Mice
MH  - Ovalbumin/administration & dosage
MH  - Proanthocyanidins/*administration & dosage
MH  - Th2 Cells/immunology/metabolism
PMC - PMC4438945
EDAT- 2015/03/05 06:00
MHDA- 2016/01/09 06:00
PMCR- 2015/02/26
CRDT- 2015/03/05 06:00
PHST- 2014/04/04 00:00 [received]
PHST- 2014/12/19 00:00 [accepted]
PHST- 2015/03/05 06:00 [entrez]
PHST- 2015/03/05 06:00 [pubmed]
PHST- 2016/01/09 06:00 [medline]
PHST- 2015/02/26 00:00 [pmc-release]
AID - mmr-12-01-0071 [pii]
AID - 10.3892/mmr.2015.3391 [doi]
PST - ppublish
SO  - Mol Med Rep. 2015 Jul;12(1):71-6. doi: 10.3892/mmr.2015.3391. Epub 2015 Feb 26.